293 related articles for article (PubMed ID: 30679322)
1. ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.
Goossens S; Wang J; Tremblay CS; De Medts J; T'Sas S; Nguyen T; Saw J; Haigh K; Curtis DJ; Van Vlierberghe P; Berx G; Taghon T; Haigh JJ
Haematologica; 2019 Aug; 104(8):1608-1616. PubMed ID: 30679322
[TBL] [Abstract][Full Text] [Related]
2. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic dysregulation of ZEB1 is involved in LMO2-promoted T-cell acute lymphoblastic leukaemia leukaemogenesis.
Wu C; Li J; Tian C; Shi W; Jiang H; Zhang Z; Wang H; Zhang Q; Sun W; Sun P; Xiang R; Yang S
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2511-2525. PubMed ID: 29778661
[TBL] [Abstract][Full Text] [Related]
4. Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.
Shields BJ; Alserihi R; Nasa C; Bogue C; Alexander WS; McCormack MP
Leukemia; 2015 Apr; 29(4):927-38. PubMed ID: 25283843
[TBL] [Abstract][Full Text] [Related]
5. ZEB2 in T-cells and T-ALL.
De Coninck S; Berx G; Taghon T; Van Vlierberghe P; Goossens S
Adv Biol Regul; 2019 Dec; 74():100639. PubMed ID: 31383581
[TBL] [Abstract][Full Text] [Related]
6. Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.
Li L; Mitra A; Cui K; Zhao B; Choi S; Lee JY; Stamos DB; El-Khoury D; Warzecha C; Pfeifer K; Hardwick J; Zhao K; Venters B; Davé UP; Love PE
Blood; 2020 Jun; 135(25):2252-2265. PubMed ID: 32181817
[TBL] [Abstract][Full Text] [Related]
7. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal.
McCormack MP; Young LF; Vasudevan S; de Graaf CA; Codrington R; Rabbitts TH; Jane SM; Curtis DJ
Science; 2010 Feb; 327(5967):879-83. PubMed ID: 20093438
[TBL] [Abstract][Full Text] [Related]
8. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
[TBL] [Abstract][Full Text] [Related]
9. Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity.
Wang J; Farkas C; Benyoucef A; Carmichael C; Haigh K; Wong N; Huylebroeck D; Stemmler MP; Brabletz S; Brabletz T; Nefzger CM; Goossens S; Berx G; Polo JM; Haigh JJ
PLoS Biol; 2021 Sep; 19(9):e3001394. PubMed ID: 34550965
[TBL] [Abstract][Full Text] [Related]
10. Activation of the
Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
[TBL] [Abstract][Full Text] [Related]
11. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
[TBL] [Abstract][Full Text] [Related]
12. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels.
Miyashita K; Kitajima K; Goyama S; Kitamura T; Hara T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2310-2316. PubMed ID: 29278703
[TBL] [Abstract][Full Text] [Related]
14. LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.
Morishima T; Krahl AC; Nasri M; Xu Y; Aghaallaei N; Findik B; Klimiankou M; Ritter M; Hartmann MD; Gloeckner CJ; Stefanczyk S; Lindner C; Oswald B; Bernhard R; Hähnel K; Hermanutz-Klein U; Ebinger M; Handgretinger R; Casadei N; Welte K; Andre M; Müller P; Bajoghli B; Skokowa J
Blood; 2019 Oct; 134(14):1159-1175. PubMed ID: 31366618
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition.
Abdulla HD; Alserihi R; Flensburg C; Abeysekera W; Luo MX; Gray DHD; Liu X; Smyth GK; Alexander WS; Majewski IJ; McCormack MP
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36920307
[TBL] [Abstract][Full Text] [Related]
16. Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.
García-Ramírez I; Bhatia S; Rodríguez-Hernández G; González-Herrero I; Walter C; González de Tena-Dávila S; Parvin S; Haas O; Woessmann W; Stanulla M; Schrappe M; Dugas M; Natkunam Y; Orfao A; Domínguez V; Pintado B; Blanco O; Alonso-López D; De Las Rivas J; Martín-Lorenzo A; Jiménez R; García Criado FJ; García Cenador MB; Lossos IS; Vicente-Dueñas C; Borkhardt A; Hauer J; Sánchez-García I
EMBO J; 2018 Jul; 37(14):. PubMed ID: 29880602
[TBL] [Abstract][Full Text] [Related]
17. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
[TBL] [Abstract][Full Text] [Related]
18. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.
Latchmansingh KA; Wang X; Verdun RE; Marques-Piubelli ML; Vega F; You MJ; Chapman J; Lossos IS
Mod Pathol; 2022 Sep; 35(9):1220-1226. PubMed ID: 35322192
[TBL] [Abstract][Full Text] [Related]
19. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
[TBL] [Abstract][Full Text] [Related]
20. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.
Jevremovic D; Roden AC; Ketterling RP; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2016 Feb; 145(2):180-90. PubMed ID: 26796495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]